New 3D Heart-Mapping tool could sharpen AFib ablation

NCT ID NCT06895187

Not yet recruiting Disease control Sponsor: LUMA Vision Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study tests a new device called the VERAFEYE System, which creates a 3D model of the heart to guide doctors during catheter ablation for paroxysmal atrial fibrillation (a type of irregular heartbeat). About 100 adults who are already scheduled for ablation will have the procedure guided by this system. The main goal is to see if doctors can successfully complete the ablation using the VERAFEYE's 3D map.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VERAFEYE System (imaging and navigation device)
What this could lead to: If successful, this could make catheter ablation for atrial fibrillation more precise and effective, potentially reducing the need for repeat procedures.
What could go wrong: This is an early-stage, non-randomized study with only 100 participants. The device may not improve outcomes over standard methods, and risks of ablation (like bleeding or heart damage) still apply.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation paroxysmal atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAROXYSMAL ATRIAL FIBRILLATION

More trials for these conditions

Other studies related to the condition(s) this trial covers.